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 GLOSSARY 
AF  - Amniotic fluid  
DPPC  - Dipalmitoyl phosphatidyl choline 
FLM  - Fetal lung maturity 
GDM  - Gestational diabetes mellitus 
HMD  - Hyaline membrane disease 
IUGR  - Intra uterine growth restriction 
LBC  - Lamellar body count 
L/S ratio - Lecithin sphingomyelin ratio 
NPV  - Negative predictive value 
PPV  - Positive predictive value 
PPROM - Preterm premature rupture of membranes 
RDS  - Respiratory distress syndrome 
PET  - Preeclamptic toxemia 
PG  - Phosphatidylglycerol 
PI  - Phosphatidylinosital 
μgm/ml - micro gram per ml 
μl  - micro liter  
μm  - micro meter  
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 INTRODUCTION 
 
The primary objective in the management of many high risk pregnancies is to 
effect timely delivery in order to: 
1. Prevent maternal morbidity and mortality. 
2. Deliver a baby in an optimal condition and thereby minimizing perinatal 
morbidity and mortality. 
 In many high risk pregnancies, prematurity and consequent respiratory distress 
syndrome (RDS) remains a common cause of neonatal morbidity and mortality. 
Hence fetal lung maturity testing plays an important role in establishing obstetric 
strategy.  
 
Respiratory distress syndrome (RDS) is an acute illness, usually of preterm 
infants, developing within 4-6 hours of birth.1      
 
Approximately 2-3 percent of infants develop respiratory distress soon after birth. 
The overall incidence is 10-15%, but can be as high as 80% in neonate <28 
weeks.2  
 
The risk of RDS is inversely proportional to gestational age.3 The introduction of 
treatments such as prenatal corticosteroids and prophylactic surfactant has reduced 
the rates of RDS at each gestational age.4 
 The accurate antenatal prediction of fetal lung maturity (FLM), based on results 
from amniotic fluid samples, is of utmost importance in the prevention of neonatal 
respiratory distress syndrome and its complications. The traditional as well as the 
current “gold standard” approach to such testing involves analysis of amniotic 
fluid (AF) by thin-layer chromatography to determine the lecithin-sphingomyelin 
ratio (L/S) and detect the presence of Phosphatidylglycerol. Although reliable, 
these chromatography methods are time consuming, costly, technique-dependent 
and not available at most institutions.  
 
A number of alternatives have been evaluated; however each lacks sensitivity or 
specificity or is rendered invalid by contamination of amniotic fluid with blood or 
meconium.  In 1989, Dubin5 described lamellar body count (LBC) in amniotic 
fluid through the use of widely available commercial cell counters.  
 
This study was conducted to evaluate the validity of amniotic fluid lamellar body 
count as a screening test for fetal lung maturity. 
 REVIEW OF LITERATURE 
 
In the 1950s, it was discovered that the resistance of pulmonary alveoli to collapse 
during expiration was mainly caused by surfactants. Since then many tests were 
described to measure the surfactant level. 
 
The lecithin /sphingomyelin ratio test, which was initially introduced by Gluck et 
al6 in 1971 remains one of the most commonly used tests, and one of the 
standardized tests against which all other tests are compared.  
 
Donald et al7 found that of those infants with lecithin / sphingomyelin ratio of less 
than 2 at the time of delivery, the morbidity from RDS was 63% with an 
associated 23% mortality rate from RDS. 
 
Hallman et al8 found that the presence of Phosphatidylglycerol in the amniotic 
fluid indicates the pulmonary maturity and also found that the false positive rate 
was 1.8%. This rate is significantly lower than the false positive rate of L/S ratio 
which was about 5%. 
 
Torday et al9 compared the measurement of the L/S ratio to that of Saturated 
Phosphatidylcholine (SPC) in high risk pregnancies and found that the SPC is 
superior for the prediction of pulmonary immaturity. 
  
Clements et al10 found that the shake test was comparable to the L/S ratio and had 
a high predictive value for RDS when applied to uncontaminated amniotic fluid. 
 
Turner and Read et al11 found that the optical density at 650nm was a better 
predictor of fetal lung maturity.  
 
In 1989, Dubin described a method for quantifying the lamellar body number 
density (lamellar body count) in amniotic fluid through the use of widely available 
commercial cell counters. 
 
Several studies have demonstrated a high correlation between the lamellar body 
count and other methods used in fetal lung maturity testing.  
 
1. A two years prospective clinical outcome study conducted by Lee IS et al12 
at the Department of Obstetrics and Gynecology, University of Ulsan, 
Korea to evaluate the usefulness of amniotic fluid lamellar body count 
(LBC) as a screening test for fetal lung maturity concluded that the LBC 
cut off value of 50,000/μl have the diagnostic sensitivity and specificity of 
100% and 80% respectively. 
 
 2. The prospective study conducted by Khazardoost et al13 at Tehran 
University of Medical Science, Iran to find out the sensitivity and 
specificity of LBC in amniotic fluid to predict fetal lung maturity 
concluded that the negative predictive value of LBC more than 50,000/μl 
was 92% and positive predictive value was 48% and sensitivity for 
prediction of RDS was 85% and specificity was 70%. 
 
3. The majority of published reports used a COULTER brand of hematology 
analyzer. One study14 used lamellar body counts from four different 
analyzers to assess fetal lung maturity. Of the four analyzers, the 
COULTER brand analyzer was found to be the best. The SYSMEX XE-
2100 showed the best concordance (86%) with the coulter. The 
concordance of ADVIA 120 was 78%. Finally the concordance of the 
CELL-DYN 3500 with the coulter was 66%. 
 
4. Lamellar body counts determined by light microscopy correlate well with 
results obtained for lamellar body counts using standard coulter counter 
techniques. (Laura A Hunter et al15) 
 
5. Ashwood et al16 reported that LBC is a good predictor of FLM, and they 
recommended a cut off of 50,000/μl as the decision threshold, with no cases 
of RDS above 48,000/μl. 
 6. Carlos et al17, conducted a prospective clinical outcome study among 130 
women stated that LBC exceeding 30,000/μl predict pulmonary maturity 
correctly in all cases. He also reported that phospholipids analysis is not 
needed with LBCs >30,000/μl or <10,000/μl, but may be of benefit for 
values in the intermediate group. 
 
7. Lewis PS, Lauria et al18 conducted a study, and concluded that testing only 
specimens where LBC >8000/μl and <32,000/μl for the L/S ratio or 
phosphatidyl glycerol would preclude the need for 76% of all that assays. 
 
8. Karcher R et al19 conducted a study in 2005 and concluded that LBC and 
TDx FLM tests are equally accurate. 
 
9. De Roche et al20 conducted a study at Department of Obstetrics and 
Gynecology, Hartford Hospital, USA states that a lamellar body count of 
more than 37,000/μl correlated well with the L/S ratio and 
Phosphatidylglycerol value in pregnancies of diabetic patients. 
 
10. Darlynn et al21 had done a project to compare a FLM test, LBC in diabetic 
and non diabetic pregnancies  and concluded that there was no statistically 
significant difference  of the LBC between diabetic and non diabetic cases  
with the gestational ages (32-34weeks) studied. 
  
11. A study22 conducted in the Department of Obstetrics and Gynecology, 
Lithuania concluded that with a cut off of 28,000/μl the diagnostic accuracy 
for LBC as follows: Sensitivity 95.2%, specificity 88%, positive predictive 
value 64.5% and negative predictive value 98.8%. 
 
12. LDE Wijnberger et al23 done a meta analysis of six studies reported that the 
performance of both L/S ratio and LBC are equal in predicting RDS. 
 
13. Shohreh Bahasadri et al24 conducted a study in Tehran  concluded that 
using the cut off  of 10,000/μl and 45,000/μl  LBC can serve as the first 
screening test for FLM. 
 
14. Geross, FN Bever et al25 done a cost effective analysis by comparing LBC 
and L/S ratio in 2002 concluded that LBC efficacy is equal to L/S ratio, and 
a cascade approach results in 80% savings to the hospital if the L/S ratio 
and percentage phosphatidyl glycerol are not done. 
 
 
 RESPIRATORY DISTRESS SYNDROME (RDS) 
 
Respiratory distress syndrome of the newborn is otherwise called as Hyaline 
Membrane Disease (HMD) which is characterized by grunting, intercostal 
retraction, nasal flaring, cyanosis in room air and requirement of oxygen to 
maintain adequate arterial oxygen pressure. 
 
Incidence: 
HMD occurs in more than 50% of babies born before 28weeks of gestation, but 
only in less than 30% of those born between 32 and 36 weeks2. 
 
Pathophysiology: 
Respiratory distress syndrome occurs because of inadequate production of 
pulmonary surfactant by the type II alveolar cells of the newborn. 
 
The surfactant spreads in the lung tissue – air interface and differentially reduces 
the surface tension of the alveoli leading to stability of the alveoli there by 
preventing alveolar collapse during expiration and allowing the alveoli to open 
easily at the next inspiration.  
 
Surfactant: 
There are two types of alveolar epithelial cells.  
 Type I cells contain less subcellular organelles and these cells spread out thinly 
along the alveolar walls and comprise the alveolar epithelium. 
 
Type II cells contain abundant mitochondria, endoplasmic reticulum, golgi 
apparatus and osmophilic lamellar bodies that contain surfactant. 
 
Surfactant production starts in the 20th week of gestation and attains maximum 
level at 35th week of gestation4. 
 
Surfactant Composition29: 
The pulmonary surfactant is a heterogeneous mixture of phospholipids (80%), 
proteins (10%) and neutral lipids (10%). 
Dipalmitoyl phosphatidylcholine (DPPC) also referred as lecithin is the main 
component of the pulmonary surfactant.  
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FIGURE 1. Glycerophospholipid composition of mature surfactant. 
80% Phosphatidylcholine 
 
2% Phosphpatidylinositol 
 
11% Phosphatidylglycerol 
 
5% Phosphatidylethanolamine 
 
2% Sphingomyelin 
 In addition to the phospholipid components of surfactant, recently four surfactant 
related proteins have been described. They are  
1. Surfactant Protein A (SP-A) 
2. Surfactant Protein B (SP-B) 
3. Surfactant Protein C (SP-C) 
4. Surfactant Protein D (SP-D) 
 
Surfactant Pathway  
After its synthesis DPPC accumulates in osmophilic structures called lamellar 
bodies. The lamellar bodies are released from the cells into alveolar fluids, from 
there they go into the amniotic fluid. This makes it possible to assess the 
biochemical maturation of the fetal lungs by studying the amniotic fluid 
phospholipid composition. 
 
Pathology  
In HMD, on macroscopic examination, the lungs appear deflated, have the 
consistency of liver and do not float in water. 
 
Microscopically there are homogeneous eosinophilic membrane (Hyaline 
membrane) plastering the alveolar ducts and the terminal bronchioles. Other 
characteristic pathological changes are small fragments of basophilic material with 
in the eosinophilic membrane, capillary congestion and lymphatic dilatation. 
  
Aetiology  
Factors predisposing to RDS are: 
 
Maternal factors 
Diabetes 
Hypertension 
Multiple Pregnancy 
Malnutrition 
Familial Disposition 
 
Perinatal factors  
Premature delivery 
Cesarean section 
Male gender 
Birth asphyxia 
Hypothermia 
Hemolytic disease of the new born 
 Prematurity 
Inadequate production of surfactant is the cause of RDS in prematurity. 
 
Cesarean Section 
Cesarean Section increases the risk of neonatal respiratory distress twofold for 
elective procedures and tenfold for emergency procedures30. The reason for this 
increased risk of respiratory morbidity following cesarean section is probably a 
combination of delayed removal of lung fluid and exaggerated pulmonary 
hypertension. 
Male Gender 
The delay in producing mature surfactant in male fetuses may be due to an 
androgen effect on type II pneumocytes30. 
 
Birth Asphyxia 
During asphyxia, lung perfusion falls to very low levels, causing ischemic damage 
to pulmonary capillaries which in turn leads to leakage of protein rich fluid from 
damaged capillaries into the alveoli where surfactant will be inactivated. 
 
Hemolytic Disease of the Newborn (HDN)   
A possible mechanism is via elevation of insulin levels due to β-islet cell 
hypertrophy.  In the presence of severe erythroblastosis with anaemia, heart 
failure, hydrops fetalis surfactant inactivation can occur. 
 Maternal Diabetes   
Insulin has been shown to delay the maturation of type II pneumocytes with 
delayed appearance of phosphatidylglycerol and decrease the proportion of 
saturated phosphatidylcholine in surfactant. 
 
Maternal Hypertension 
Maternal hypertension increases the risk of RDS, probably as a result of preterm 
delivery by elective cesarean section before the onset of labor. 
 
Multiple Pregnancy 
In twin pregnancies, the second twin is usually at greater risk of developing RDS. 
It is not clear whether this increased risk is due to delayed maturation of the lungs 
or an increased risk of asphyxia in the second twin. 
 
Malnutrition 
Deficiency of inositol might be important in this cases and supplementation of 
preterm infants has been shown to promote maturation of surfactant 
phospholipids. 
 
Familial Predisposition 
Familial RDS is due to congenital deficiency of SP-B. 
 
 Factors protecting against RDS 
1. Antenatal Corticosteroids 
2. IUGR 
3. Premature rupture of membranes (PROM) 
4. Maternal drugs and smoking 
5. Female gender  
6. Ethnicity 
 
1. Antenatal Corticosteroids 
Meta analysis of all randomized controlled trials (RCT) suggests an 
approximate 50% reduction of risk of RDS and a 40% reduction of neonatal 
mortality31. 
 
2. IUGR 
A stressful intrauterine environment might increase the production of 
glucocorticoids and catacholamines in fetal plasma, leading to earlier 
maturation of the fetal lungs and reduced risk of RDS. 
 
3. PROM 
PROM over a short period of time decreases the RDS as a result of stress 
hormones and increases the production of surfactant. 
 
 4. Maternal Drugs and Smoking 
Maternal narcotic addictions, cocaine use, smoking and alcohol intake all 
reduces the incidence of RDS in preterm babies. 
 
5. Gender 
Girls have less RDS at each gestational age compared with boys. 
 
6. Ethnicity 
Black infants have a lower incidence of RDS than white infants. 
 
CLINICAL SIGNS 
The clinical signs (Respiratory distress scoring by Silverman) and the radiological 
criteria for the diagnosis of RDS are as below: 
RESPIRATORY DISTRESS SYNDROME SCORING BY SILVERMAN4 
Score 0 1 2 
Respiratory rate <60/m 60-80/m >80/m 
Cyanosis None None / 40% O2 Requires >40% O2 
Chest retraction  None Mild Moderate to Severe 
Grunting None Audible with 
stethoscope 
Audible without 
stethoscope 
Air entry  Good Decreased Barely audible 
 
Score of 0-3 – mild RDS 
      4-6 – moderate RDS 
      7-10 – severe RDS 
  X-ray picture suggestive of RDS are  
1. Granular pattern 
2. Ground glass appearance  
3. Air bronchogram 
PREVENTION 
Antenatal corticosteroids have been proved to decrease the incidence of RDS. A 
meta analysis has shown that prophylactic surfactant therapy, that is given with in 
10-15 minutes of birth, leads to reduced mortality for infants of 31weeks of 
gestation or less4.  
 
TREATMENT 
1. The baby should be placed in the intensive neonatal care unit. Warmth, 
humidified oxygen, correction of hypovolaemia, correction of electrolyte 
imbalance, prevention of infections, maintenance of nutrition are the 
mainstay of the treatment. 
2. Surfactant Therapy – it has significantly improved the outcome of infant 
with HMD.  
3. Mechanical Ventilation is needed for severe RDS. 
 
PROGNOSIS 
About one third of the babies may die. In mild affection with good vigor the baby 
may survive3. 
 SPECIFIC TESTS FOR THE ASSESSMENT OF FETAL LUNG 
MATURITY 
A. Biochemical quantitation of pulmonary surfactant  
Lecithin / Sphingomyelin Ratio (L/S ratio) 
Phosphatidyl glycerol (PG) 
Lung Profile 
Saturated Phosphatidylcholine (SPC) 
Microviscosimeter 
Fluorescent polarization (surfactant / albumin ratio) 
Surfactant – associated proteins 
 
B. Biophysical measurement of surfactant function 
Shake test 
Foam stability index 
Tap test 
 
C. Evaluation of amniotic fluid turbidity 
Visual inspection  
Optical density at 650nm 
Lamellar body counts 
 BIOCHEMICAL QUANTITATION OF PULMONARY SURFACTANT 
 
 1. Lecithain / Sphingomyelin Ratio (L/S ratio) 
The L/S ratio test, which was initially introduced by Gluck et al6 in 1971 remains 
the “gold standard” test. 
The total phospholipids in amniotic fluid increase throughout gestation and there 
is a sharp increase at 35 weeks. Concentration of lecithin and sphingomyelin are 
equal until 35 weeks of gestation, when there is an increase in lecithin 
concentration, to almost four times that of sphingomyelin. Sphingomyelin is not 
related to maturation event. 
The L/S ratio for normal pregnancy is less than 0.5 at 20 weeks gestational age 
and gradually increases to a value of 1 at about 32 weeks gestational age. A value 
of 2 was achieved by 35 weeks gestational age6.  
RDS is very unlikely if the L/S ratio is more than 232. 
False positive rate is 2.7%. 
False positive rate in Diabetic mothers with L/S ratio more than 2 is 7.4% 
 
Disadvantages: 
1. Both blood and meconium staining of amniotic fluid is found to interfere 
with L/S ratio determinations33. 
2. Requirements for expensive equipment and well trained personnel. 
3. Time consuming. 
 4. Costly. 
5. Not available in many smaller hospitals. 
 
1. Phosphatidylglycerol and phosphatidylinositol 
 
Phosphatidylglycerol and phosphatidylinositol comprise smaller fractions of 
surfactant. Phosphatidylinositol peaks at 35 weeks gestation and dramatically 
decreases as term approaches8,34. In contrast, Phosphatidylglycerol is barely 
detectable until 35 weeks gestation, when it first appears. Then its concentration 
increases with gestation. Thus presence of Phosphatidylglycerol in amniotic fluid 
indicates fetal lung maturity. 
 
Phosphatidylglycerol may not be as gestational age dependent as L/S ratio. 
False positive for Phosphatidylglycerol determination was 1.8%. 
Phosphatidylglycerol determination originally required thin layer chromatography, 
trained personnel and expensive equipment. But with the development of rapid 
slide agglutination test, termed as Amniostat FLM (AFLM), Phosphatidylglycerol 
estimation has become less expensive, faster and could be performed by untrained 
personnel. Phosphatidylglycerol concentration more than 2μgm/ml or 2% of total 
phospholipids indicates fetal lung maturity.  
 
 
 3. LUNG PROFILE 
The lung profile includes the L/S ratio, desaturated lecithin, Phosphatidylglycerol 
and phosphatidylinositol concentrations. The false positive rate was reduced to 
less than 1% with the combined lung profile test34. 
 
4. SATURATED PHOSPHATIDYLCHOLINE  
Saturated Phosphatidylcholine in amniotic fluid is found to be superior to L/S ratio 
for prediction of pulmonary immaturity. The cut off value of Saturated 
Phosphatidylcholine more than 500μgm/dl indicates fetal lung maturity9.  In 
addition the Saturated Phosphatidylcholine was found to be valid in the presence 
of blood and meconium. A significant draw back is the requirement of thin layer 
chromatography and skilled personnel.  
 
5. MICROVISCOSIMETER 
Microviscosimeter testing measures surfactant associated with a phospholipid 
membrane using florescent dye techniques. 
 
6. FLUORESCENT POLARIZATION (SURFACTANT / ALBUMIN 
RATIO) 
A recently introduced TDx FLM assay is an automated fetal lung maturity test 
based on the principle of fluorescent polarization. It only requires approximately 
1ml of amniotic fluid. The TDx FLM assay provides a quantitative, rapid and 
 automated measurement of the amniotic fluid surfactant to albumin ratio. A 
surfactant to albumin ratio of 50-70 mg surfactant /gm of albumin has been 
considered mature in most studies35. 
Biophysical measurement of surfactant function 
 
1. Shake Test And Foam Stability Index. 
These two tests use the principle that when ethanol is added to amniotic fluid, 
the non surfactant foam causing substances in amniotic fluid are removed. Any 
stable foam layer that persists after shaking is due to the presence of surfactant 
in a critical concentration. When the shake test predicts maturity, its accuracy 
is close to 100%, but a negative test is not a good predictor of pulmonary 
immaturity10. 
 
Foam stability index 
This is a semi-quantitative test. In this test the fluid is mixed with ethanol in 
the necessary amounts to achieve alcohol concentrations ranging from 44% to 
50%. 
A positive foam stability index at an ethanol concentration of 47% is a better 
predictor of fetal lung maturity36. 
2. Tap Test 
This test is performed by mixing 1ml of amniotic fluid with one drop of 6N 
hydrochloric acid and then adding 1.5ml of diethyl ether. The test tube is 
 briskly tapped creating bubbles in the ether layer. If the fetus is mature, the 
bubbles will rise to the surface and break down. If the fetus is immature, 
bubbles are stable or break down slowly37. 
Similar to other tests, it has positive predictive value 98% to 100%, but the 
negative test is not a good predictor of fetal lung maturity. 
Evaluation of Amniotic Fluid Turbidity 
 
1. Visual Inspection 
Visual comparison of the turbidity of unspun amniotic fluid against positive 
(mature) or negative (immature) controls predicts the fetal lung maturity and 
immaturity with good sensitivity and specificity38.  
2. Optical density at 650nm 
The measurement of the amniotic fluid optical density at 650nm value between 0.1 
and 0.2 predicts fetal lung maturity11. 
 
3. Lamellar body count  
Lamellar bodies are concentrically layered structures produced by type II 
pneumocytes, which are extruded into the lung fluid and can enter the amniotic 
fluid via the fetal mouth.  
They are comprised of phospholipids that represent the storage form of surfactant 
and have a similar size to platelets, ranging from 1 to 5μm in diameter14. 
 Therefore, by performing a “platelet count” on amniotic fluid, a count of lamellar 
bodies (LBC) will be obtained by using automated cell counter. 
 
Amniotic fluid can be collected by the following methods: 
1. Amniocentesis 
2. During cesarean section. 
3. Vaginal pool specimen composed of free flowing amniotic fluid (Not 
contaminated with mucous). 
Minimum of 1ml is required. The uncentrifuged specimens are used for lamellar 
body count. 
 
Recently, a consensus LBC protocol14 was published and a fetal lung maturity was 
suggested by a cut off of 50,000/μl or greater and immaturity was suggested by a 
count of 15,000/μl or lower regardless of the hematology analyzer and also states 
that centrifugation is not a necessary step and should be abandoned. 
 
Coulter type of hematology analyzer is commonly used, but sysmex also gives 
almost equal results. Many studies proved that lamellar body count correlates 
positively with advancing gestational age and its efficacy is comparable to L/S 
ratio and phosphatidyl glycerol estimation. 
 
 
 Lamellar body count determined by light microscopy correlates well with the 
results obtained from Coulter counter.   
 
The advantages are  
1. It is rapid, simple, more precise, more objective, inexpensive    and universally 
available. 
2. Meconium and lysed blood will not interfere with LBC. However EDTA 
(ethylene diamino tetra acetic acid) treated blood may artificially decrease the 
count.33 
3. Vaginal pool specimens composed of free flowing amniotic fluid will be 
usable6. (Those vaginal pool specimens contaminated with mucous cannot be 
tested) 
4. In diabetic patients, LBC is more reliable than L/S ratio20.  
 
 
 
 
 
 
 
 
  
 
AIM OF THE STUDY 
 
To evaluate the efficacy of amniotic fluid lamellar body count (LBC) as a 
screening test for fetal lung maturity. 
 
 MATERIALS AND METHODS 
 
STUDY DESIGN 
 
A prospective clinical outcome study for assessing the efficacy of amniotic fluid 
lamellar body count as a screening test for fetal lung maturity. 
 
PLACE OF STUDY AND STUDY POPULATION 
 
This study was conducted over a period of one year, (July 2005 to June 2006) 
among the patients admitted in the Government Kasturba Gandhi Hospital, 
Madras Medical College at Chennai. 
 
Total number of 115 cases were included in the study using certain inclusion 
criteria. The study group consisted of patients irrespective of age, parity, booking 
status and socioeconomic status with risk factors for RDS. 
 
Amniotic fluid lamellar body count from 115 pregnant women between 28 weeks 
and 40 weeks of gestation were evaluated. The patients with the confounding 
factors which would have their own influence on respiratory distress syndrome 
were excluded from the study even at that point of time. So, the results could be 
derived with only 100 patients in this study population. 
  
INCLUSION CRITERIA 
1. Preterm labor. 
2. Premature rupture of membranes. (PROM) 
3. Preeclamptic toxemia. (PET) 
4. Repeat cesarean section. 
5. Diabetes. 
6. Intra uterine growth restriction. (IUGR)  
 
EXCLUSION CRITERIA 
1. Birth asphyxia. 
2. Meconium stained liquor. 
3. Sepsis. 
4. Jaundice. 
5. Patients delivered   after steroid treatment. 
 
METHODS OF STUDY 
Amniotic fluid was collected by the following methods: 
1. Amniocentesis (under USG guidance, after getting informed consent, trans 
abdominal amniocentesis was performed). 
2. During cesarean section. 
 3. Free flowing amniotic fluid (not contaminated with mucous) flowing 
through the cervical os  
Minimum of 1ml was collected, refrigerated. Lamellar body count was obtained 
from the uncentrifuged specimens by using platelet channel of commercial cell 
counter (Sysmex). A balanced electrolyte solution was aspirated at least once into 
the instrument to prime it and to remove any remaining blood that might have 
been left on the tip from previous analyses. Then the amniotic fluid specimens 
were aspirated into the Sysmex counter, the platelet channel measures the number 
and size of the particles that are 1-5μm in diameter which corresponds to lamellar 
body counts. 
 
Recently a consensus lamellar body count protocol14 was published, and a fetal 
lung maturity cut off of 50,000/μl was suggested with out discussion regarding the 
hematology analyzer used. The Lamellar body count of 50,000/μl was chosen as a 
cut off point for the fetal lung maturity. 
 
After delivery, each infant was evaluated for any evidence of respiratory distress 
syndrome. Standard clinical and radiographic criteria were used to diagnose 
respiratory distress syndrome. 
 
The variables studied included examination of the preterm infant with specific 
reference to   
 1. Sex/weight/apgar score (1 minute apgar) 
2. Gestational age 
3. Evidence of respiratory distress syndrome and score by Silverman 
4. Evidence of  
a. Hypoglycemia 
b. Jaundice 
c. Hypothermia 
d. Birth asphyxia 
e. Sepsis 
f. Bronchopneumonia 
5. In case of infant death, time and cause of death were noted. 
 
When respiratory distress was present for the baby, an x-ray chest was taken as the 
chief investigation. 
X-ray picture of  
4. Granular pattern 
5. Ground glass appearance  
6. Air bronchogram 
were taken as evidence of Idiopathic respiratory distress syndrome. 
 RESULTS AND ANALYSIS 
 
Out of a total of 115 patients studied initially, 100 patients were included in the 
study finally.  
TABLE 1. AGE DISTRIBUTION 
n=100 
 
Sl.No Age Group(yrs) Number of 
Patients 
% of Patients 
1 ≤20 12 12 
2 21-25 53 53 
3 26-30 30 30 
4 31-35 5 5 
5 ≥36 0 0 
 
 
• In this study majority of the patients were in the age group of 21-30yrs, 
which accounts for 83%, and none of the patients were above 35yrs. 
 
 TABLE 2. BOOKING STATUS 
 
 
Sl.No Booking Status Number of 
Patients 
% of Patients 
1 Booked 95 95 
2 Unbooked 5 5 
 
 
• 95% of the patients were booked, either in this hospital or in other 
hospitals. 
• Effective antenatal care helps in proper screening of the patients and 
identifying the at risk patients for RDS.  
 
 
 TABLE 3. SOCIO ECONOMIC STATUS 
 
 
Sl.No Socio Economical 
class 
Number of Patients % of Patients 
1 Class I 0 0 
2 Class II 0 0 
3 Class III 4 4 
4 Class IV 13 13 
5 Class V 83 83 
 
 
• Majority of the patients belonged to class V socio economical class, since 
this hospital essentially caters to those below poverty line. 
 TABLE 4. GRAVIDITY DISTRIBUTION  
 
 
Sl.No Gravidity Number of Patients % of Patients 
1 Primi gravida 52 52 
2 Second gravida 29 29 
3 Third gravida 15 15 
4 Fourth gravida and 
above 
4 4 
 
 
• Primi gravida contributes to 52% of the study population, second and third 
gravida accounts for 44% and the gravida four and above accounts for only 
4%. 
 TABLE 5. RISK FACTORS 
 
Sl.No Risk factors Number of Patients % of Patients 
1 Preterm labor 44 44 
2 Repeat cesarean 
section 
17 17 
3 Preeclamptic 
toxemia  
16 16 
4 Diabetes 
complicating 
pregnancy 
10 10 
5 PPROM 11 11 
6 IUGR 2 2 
 
 
• The various indications for assessing the lamellar body count are given in 
this table. 
• In this study 44% of the patients had preterm labor without any other risk 
factors for RDS. 
• In the above data pre term patients with other risk factors like PET, diabetes 
are not included in the pre term group and they are included in the PET, 
diabetes group. 
• 17% of repeat cesarean section cases were also selected, since cesarean 
section is also one of the risk factors for RDS. 
• 2 cases of IUGR (protecting factor) were also included. 
 TABLE 6. GESTATIONAL AGE 
 
Sl.No Gestational Age 
(weeks) 
Number of Patients % of Patients 
1 28-31 18 18 
2 32-35 57 57 
3 36-40 25 25 
 
 
• In this study, about 75% of the patients were with gestational age below 36 
weeks.  
• Patients with very pre term (<32 weeks) accounts for 18%, whose babies 
are more vulnerable for RDS.  
• 25% of the patients with the gestational age of 36-40 weeks were selected 
to study the impact of lamellar body count on the gestational age, that is for 
internal comparisons. 
 TABLE 7. MODE OF DELIVERY 
 
 
Sl.No Mode of 
delivery 
Number of 
Patients 
% of 
Patients 
Number of 
cases of 
RDS 
% of  
RDS 
1 Labor Natural 64 64 12 18.75 
2 
Cesarean 
Section  
30 30 6 16.6 
3 Forceps 4 4 - - 
4 Vacuum 2 2 - - 
 
 
• Two third (2/3) of the babies were delivered by labor natural. 
• In addition to the 17 cesarean section cases (both elective and emergency) 
were selected initially, 13 emergency cesarean sections were performed.  
• There was no  statisticall significant difference in the incidence of RDS 
between labor natural and cesarean section. (p value =0.8) 
 
 TABLE 8 A. SIGNIFICANT LAMELLAR BODY COUNT 
 
Sl.No LBC (per μl) Number of Patients % of Patients 
1 < 50,000 23 23 
2 > 50,000 77 77 
 
• In this study, the lamellar body count varied from 5,000/μl to 2,88,000/μl 
with a mean of 86,378/μl.  
• In 23% of the patients lamellar body count was below 50,000/μl. Only in 
5% of the patients the lamellar body count was <25,000/μl. 
 
TABLE 8B. LAMELLAR BODY COUNT  
 
Sl.No Lamellar body 
count (per μl) 
Number of Patients % of Patients 
1 ≤ 24,999 5 5 
2 25,000-49,999 18 18 
3 50,000-99,999 50 50 
4 ≥ 1,00,000 27 27 
 
 
 
 TABLE 9. LAMELLAR BODY COUNT IN RELATION TO 
GESTATIONAL AGE. 
Sl.No Gestational 
Age 
(weeks) 
Total no. 
of Patients
LBC   
<50,000/μl 
LBC 
>50,000/μl 
   Number % Number  % 
1 28-31 18 10 55.6 8 44.4 
2 32-35 57 13 22.8 44 77.2 
3 36-40 25 0 0 25 100 
 
 
• Out of the 18 patients in the gestational age of 28-31 weeks, the LBC was 
less than 50,000 in 10 signifying fetal lung immaturity.   
• In the gestational age group of 32-35 weeks, the same was only 13 out of 
57, signifying an increased lung maturity.  
• All the 25 babies were fully mature in the GA 36-40 weeks.  
• All these indicate that the lamellar body count increases, as the gestational 
age increases. 
 
 
 
 
 TABLE  10  LBC of <50,000 / μl and RDS in Different Type of Cases. 
 
 
• The above table shows predictability of RDS by LBC in each high risk 
group. 
• In different high risk group the LBC predicts RDS differently. There is no 
Statistical correlation, this is because gestational age is not standardized in 
each group. 
  
RISK Factor  Total No. of 
Patients in  
each group 
No. of Patients 
with LBC 
<50,000/ μl 
Percentage 
of Patients 
with LBC 
<50,000/ μl 
No of 
Cases of 
RDS 
Percentage of 
Cases of RDS 
Preterm  44 12 27.3 6 13.7 
PET 16 7 43.8 5 31 
IUGR 2 1 50 1 50 
PPROM 11 3 27.3 4 36 
C.S 17 0 0 2 11.8 
DM 10 0 0 0 0 
 TABLE 11. SEX OF THE BABIES 
 
 
Sl.No Sex Number of 
Babies 
% of 
Patients 
Number of 
cases of 
RDS 
% of RDS 
1 Male 59 59 11 18.6 
2 Female 41 41 7 17 
 
 
• 59% of the babies were male 
• Out of 18 cases of RDS, 11 babies were male. 
• There was no  statistically significant difference in the incidence of RDS  
between male and female babies.(p value=0.8) 
 TABLE 12.BIRTH WEIGHT OF THE BABIES 
 
 
Sl.No Birth 
Weight 
(kg) 
Number 
of Babies 
% of 
Babies 
Number of 
cases of 
RDS 
% of RDS 
1 ≤ 2 25 25 10 40 
2 2.1-2.5 32 32 8 25 
3 2.6-3.0 30 30 - - 
4 3.1-3.5 9 9 - - 
5 ≥ 3.6 4 4 - - 
 
 
• In this study, 75% of the babies had birth weight above 2kg (Most 
salvageable birth weight). 
• In this study RDS occurred only in babies with birth weight less than 2.5kg. 
•   There was a statistically significant difference in the occurrence of RDS  
among the babies with different birth weights.(p value <0.001)
 TABLE 13. ASSESSMENT OF GESTATIONAL AGE AFTER                    
                            BIRTH OF BABIES 
 
 
Sl.No Gestational age 
of Babies 
(weeks) 
Number 
of Babies 
% of 
Babies 
Number of 
cases of 
RDS 
% of RDS 
1 Term  
 
19 19 0 0 
2 Pre Term  
 
62 62 12 19 
3 Very Pre Term   19 19 6 31.6 
 
 
• Nearly 80% of the babies were pre term and 19% of the babies were very 
pre term. 
• Occurrence of RDS was very high in very pre term infants. 
• There was a statistically significant difference in the occurrence of RDS 
among the different gestational age group(p value <0.05)
 TABLE 14. RESPIRATORY DISTRESS SYNDROME (n=18) 
 
 
Sl.No LBC / μl Number of Babies developed 
RDS  
Number of 
Babies died  
1 > 50,000 3 0 
2 < 50,000 15 7 
 
 
• In this study, the incidence of RDS was 18%. Among 18 babies, 3 of those 
developed RDS had LBC count above 50,000μl and 15 of those had LBC 
below 50,000μl. Death due to RDS occurred only in those with LBC less 
than 50,000μl. 
 STATISTICAL ANALYSIS 
PREDICTION OF RDS 
Statistical attributes of lamellar body count as a screening test for fetal lung 
maturity was analyzed and found as follows: 
 
The main observation in this study was the presence or absence of RDS in the 
neonate. If death had occurred the same was recorded.  
Lamellar body count above 50,000/μl was considered as a positive test, which 
indicates fetal lung maturity. A negative test result means lamellar body count of 
below 50,000/μl. 
 
TABLE 15. ASSOCIATION BETWEEN LBC AND RDS 
 
LBC/μl NO RDS 
(Mature lung) 
RDS 
(Immature lung) 
> 50,000 74 3 
< 50,000 8 15 
 
TRUE POSITIVE 
Those individuals found positive on the test had mature fetus and the fetus did not 
develop RDS.  
a = 74 
 FALSE POSITIVE 
This denotes who had the positive test results but the fetus developed RDS. 
b = 3 
FALSE NEGATIVE 
Denotes those with negative results but did not develop RDS. 
c = 8 
TRUE NEGATIVE 
This denotes negative test results with out RDS. 
d = 15 
SENSITIVITY 
Ability of the test to identify correctly all those have mature lung, that is do not 
develop RDS. 
a*100/(a+c) = 74*100/(74+8) = 90% 
SPECIFICITY  
Ability of the test to identify correctly who do not have mature lung, that is those 
who do not develop RDS. 
d*100/(b+d) = 15*100/(3+15) = 83% 
 
POSITIVE PREDICTIVE VALUE 
This reflects the diagnostic power of the test. Predictive value of the positive test 
indicates the probability of getting mature fetus with a positive results. 
a*100/(a+b) = 74*100/(74+3) = 96% 
 NEGATIVE PREDICTIVE VALUE 
It denotes the probability of getting immature fetus with a negative test.  
d*100/(c+d) = 15*100/(8+15) = 65% 
 
TEST OF SIGNIFICANCE  
Chi-Square Test 
χ2  =    Σ ((O - E)2/E) 
 
Applying values of O and E from the above table, 
Degrees of freedom: 1  
Chi-square = 45.1185082150087  
Since p is less than or equal to 0.001, the distribution is significant.  
There is strong correlation between Screening test and fetal lung maturity. 
 
 
RELATIONSHIP BETWEEN GESTATIONAL AGE & LBC. 
Applying  values of Gestational age & LBL in the correlation co-efficient (r) 
formula, the value of +1 indicates a strong positive association between 
Gestational & LBC. 
 
 
 
   DISCUSSION 
 
This one year prospective clinical outcome study was carried out among the 100 
pregnant women in Govt. Kasturba Gandhi hospital, Chennai to evaluate the 
efficacy of amniotic fluid lamellar body count (LBC) as a screening test for fetal 
lung maturity and the results are discussed as follows.  
 
Demographic characters    (Table 1, 2, 3, 4) 
• In this study majority of the patients were in the age group of 21-30yrs, 
which accounts for 83%, and none of the patients were above 35yrs. 
• 95% of the patients were booked. 
• Majority of the patients belonged to class V socio economic class. 
• Primi contributes to 52% of the study population, 2nd and 3rd gravida 
accounts for 44% and the 4th gravida and above accounts for only 4%. 
The Demographic factors showed no statistically significant difference in 
homogeneity between the LBC <50,000/μl and >50,000/μl 
 
Risk factors and mode of delivery (Table 5, 7) 
• Various risk factors for RDS which were present in the mothers selected for 
this study were depicted in these tables.. 44% of the patients had preterm 
labor without any other complications, 17% cases of repeat cesarean section 
 cases were also included in the study. Other risk factors included were PET, 
Diabetes complicating pregnancy and PPROM. 
 
• In this study 2/3 of the patients were delivered by labor natural and 1/3 by 
cesarean section. Even though cesarean section is a risk factor for the 
occurrence of RDS, mode of delivery did not significantly affect the 
occurrence of RDS   (p=0.8) 
 
Incidence of RDS (Table 6, 12, 13) 
• The  incidence of RDS in this study was 18% which is slightly on the 
higher  side  when  compared  to  12% reported by Carlos et al17, 14% 
reported by Fakhory et al39 and 11% reported by Ahwood et al16. 
• This is probably due to high proportion of (19%) very preterm (<32weeks) 
birth in this study when compared to 11% in Carlos et al study. 
• In this study 15 out of 18 RDS cases had been correctly predicted which is 
comparable to Khazardoost et al13 study where 17  out of 20 RDS cases had 
been predicted correctly. 
• Out of 18 cases of RDS, 7 babies died due to RDS.  
• Case fatality rate was 28%   
• Death due to RDS had occurred only in the group of patients who had LBC 
<50,000/μl    
 
 Table (10, 11, 12) 
• In this study the incidence of RDS was not significantly affected by the sex 
of the babies.   
• The incidence of RDS was high in very preterm infant and babies with birth 
weight <2kg.since LBC correlates well with gestational age, it indirectly 
correlates with the birth weight also.                   
 
LBC and its validity 
• In this study, the lamellar body count  varied  from 5,000/μl to 2,88,000/μl 
with a mean of 86,378μl which is comparable to Carlos et al study ,in that 
LBC ranged from 4000μl to 3,29,000/μl. In 23% of patients LBC was 
below 50,000/μl 
• To study impact of the gestational age on the test performance, study group 
patients were divided into three groups based on four weeks gestational age 
intervals. 
Lee IS et al12 study proved that the LBC correlated positively with advancing 
gestational age. 
• The percentage of LBC <50,000/μl in the gestational age group of 28-31 
weeks was 55.6% against 22.8% in the gestational age group of 32-35 
weeks and all had LBC above 50,000/μl in the gestational age group of 36-
40 weeks.  
 • Carlos et al calculated the sensitivity, specificity, positive predictive value 
and negative predictive value for each gestational age group separately and 
found that these values were equal to or better than that for either L/S ratio 
or the phospholipids profile. 
• In the critical function of predicting fetal lung maturity, our data 
demonstrated that when using a cut off of 50,000/μl, lamellar body count 
showed 90% sensitivity, 83% specificity, 96% positive predictive value and 
65% negative predictive value. p value is <0.001 which is statistically 
significant.  
These values are comparable to other studies. 
STUDY LBC CUT 
OFF VALUE
SENSITIVITY 
% 
SPECIFICITY 
% 
PPV 
% 
NPV % 
Carlos et al17 30,000 100 72 92 100 
Ashwood et al16 55,000 95 87 98 75 
Lee Is et al12 50,000 100 80 - - 
Khazardoost et al13 50,000 85 70 48 93 
Lewis PS et al18 32,000 96 98 99 63 
Neerhof MG et al26 50,000 95 88 65 98 
Dalence CR et al27 35,000 85 98 99 63 
 
 • The negative predictive value of 65% can be improved by lowering the cut 
off value for predictive lung immaturity. Carlos et al recommended a cut 
off of 10,000/μl to predict a high likelihood of pulmonary immaturity. 
• Ashwood et al16 recommended a cut off value of 15,000/ μl to predict 
pulmonary immaturity. 
 
LAMELLAR BODY COUNT IN DIABETIC PATIENTS 
• The lamellar body counts on the samples from the 10 diabetic mothers were 
studied. All had count above 50,000μl and none had developed respiratory 
distress syndrome. De Roche ME et al20 reported that a lamellar body count 
of 37,000/μl correlated with LS ratio and phosphatidyl glycerol value in the 
pregnancies of diabetic patients. However in this study the sample size and 
the period of gestation were inadequate to analyse the results of lamellar 
body count in diabetic mothers and it needs a larger study with adequate 
sample size. 
 
ANTENATAL STEROIDS 
• Patients who received antenatal steroids and delivered  after treatment were 
excluded from the study. 12 patients received steroids and delivered with in 
24hrs of first dose. They were included in the study. 5 out of 12 babies 
developed respiratory distress syndrome, all had lamellar body count 
<50,000/μl. 
 LIMITATIONS AND LACUNAE 
1. In this study lower cut off value of predicting lung immaturity was not 
standardized. The cut off value of 50,000 was taken following the overall 
average in various studies. Only few authors have specifically reported a 
lamellar body count value below which the risk of immaturity is 
exceedingly high. However no one has made recommendations for cut off 
below which further testing would be necessary.16  
2. Even though the cell counter is available in many institutions, private 
laboratories and private hospitals, the use of amniotic fluid in the routine 
hematology analyzer needs manufacture’s explanation and 
recommendations. 
3. In this study lamellar body count is not compared with the gold standard 
L/S ratio because since it is not easily available. 
 
 SUMMARY 
 
This prospective clinical outcome study was undertaken in Government Kasturba 
Ghandhi Hospital, Chennai during the period of 2005-2006 among the 100 
pregnant women between 28 and 40 weeks of gestation, with the risk factors for 
RDS, to prove the efficacy of amniotic fluid lamellar body count as a screening 
test for fetal lung maturity. 
 
The various observations are: 
1. The demographic factors studied were age, booking status, socio economic 
status, and gravidity. They showed no statistically significant difference in 
homogeneity between the LBC <50,000 and >50,000/μl. 
 
2. Mode of delivery did not significantly affect the occurrence of RDS. 
 
3. In this study the incidence of RDS was 18%. In all cases of severe RDS the 
count was below 50,000/μl. Case fatality rate was 28%. Death due to RDS 
had occurred only in group of patients who had LBC below 50,000/μl. 
 
4. In this study LBC ranged from 5,000/μl to 2,88,000/μl. LBC correlates well 
with the gestational age, as the gestational age increase the LBC also 
increases.  
 
  
5. In predicting fetal lung maturity, the LBC showed 90% sensitivity, 83% 
specificity, 96% positive predictive value and 65% negative predictive 
values which are comparable to many other studies. 
 
6. The sample size and the duration of gestation were inadequate in this study 
to analyze the effect of LBC in diabetic patients. 
 
 CONCLUSION 
 
 
 
Management of pregnancies at risk for the development of neonatal RDS would be 
enhanced by a rapid, accurate, and objective test for fetal lung maturity. In most 
clinical settings, the most important function of a fetal lung maturity test is to 
predict accurately the absence of RDS. 
 
In many studies lamellar body count compares favorably with traditional 
phospholipids testing and L/S ratio in the prediction of fetal lung maturity.  
 
Our data indicates that using a LBC cut off of 50,000/μl to predict fetal lung 
maturity, the lamellar body count showed 90% sensitivity, 83% specificity, 96% 
positive predictive value and 65% negative predictive value. 
 
The LBC has many advantages over gold standard L/S ratio. LBC is faster, more 
precise, more objective, inexpensive, requires smaller sample volume and it is not 
invalidated by the presence of lysed blood or meconium.  In addition the 
instrumentation required for the test is almost universally available, allowing it to 
be performed in laboratories where L/S ratio or traditional phospholipid analysis is 
not available. 
 
 
  
Since LBC is cost effective, can be performed quickly and the efficacy is also 
acceptable high,  LBC may be used as the test of choice in the assessment of fetal 
lung maturity. 
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 PROFORMA 
 
AMNIOTIC FLUID LAMELLAR BODY COUNT AS A SCREENING TEST 
FOR FETAL LUNG MATURITY 
 
Sl. No: 
NAME :     AGE : IP.No: Unit: 
 
D.O. Admission:     Booked/Unbooked: 
D.O. Delivery:     Immunized /Unimmunized: 
D.O. Discharge:     Occupation: 
       Income: 
       Address: 
 
OBSTETRIC FORMULA: 
LMP : 
E.D.D: 
M/S : 
M/H : 
OBSTETRIC HISTORY – RISK FACTORS: 
Preterm / DM / PET / PROM / LSCS 
PAST MEDICAL / SURGICAL HISTORY: 
FAMILY HISTORY: 
  
EXAMINATION: 
Ht :  Wt : 
Pallor :  Edema: 
PR :  BP : 
CVS :  RS : 
ABDOMINAL EXAMINATION 
Uterus (Fundal height):   SFH : 
Acting / Not acting      :   EFW  : 
Presentation       :   Liquor: 
FHR        : 
 
P/V: 
INVESTIGATIONS: 
Hb%        VDRL 
Urine        HIV 
 Alb    : 
  
Sugar : 
 
Blood  Sugar:      Hbs Ag 
Blood grouping & Typing 
 
 
 USG: 
1st Trimester Scan    Present Scan 
 
LAMELLAR BODY COUNT 
 
LABOR 
Mode of delivery: 
Intra partum Complications: 
NEONATAL DETAILS 
Sex :       GA: 
B.Wt:       Condition at Birth: 
Apgar:  1 mt:   5 mt:  10 mt: 
DISC NO: 
DELIVERED ON: 
 
MORBIDITY:    
 NICU Admission: 
Asphyxia/RDS/Sepsis/Jaundice/Apnoea/Seizure/Bronchopneumonia/NEC 
 
MORTALITY:  Still Birth / Neonatal death   - Cause of death 
 
 
 
 
  
 
 
X – Ray pictures of neonate with RDS showing diffuse ground 
glass” appearance” 
 
 
 
 
 
  
 
 
                        SYSMEX – CELL COUNTER  
 
 
 
 
                            Preterm Neonate with RDS  
 
 
 
                Lamellar bodies in the cytoplasm of type to Cells. 
 
MASTER CHART BABY DETAILS
Sl. No NAME/IP NO. Age B/UB SES Gravidity
Risk
Factor GA
Mode of
delivery LBC SexB.Wt. GA Apgar
RDS
Scoring Mortality
1 PADMAPRIYA-6148 21 B V P PT 35 LN 75000 M 2.6 PT >7
2 POORNIMA-6169 21 B IV P PT 33 LN 64000 F 2.2 PT >7
3 KAVITHA-6187 24 UB V G2 PET 34 LN 79000 F 2.8 PT >7
4 ANJUGAM-6228 28 B V G3 C.S 39 EM.C.S 152000 M 3.4 T >7
5 ABIRAMI-6168 22 B V G2 PT 31 LN 50000 M 1.9 VPT >7
6 FATHIMA-6304 18 B V P PPROM 32 LN 24000 M 2 PT 5-7 mild RDS
7 NIRMALA-6158 21 B V P PT 31 LN 48000 M 2.2 VPT >7
8 MANJULA-6256 33 B V G5 C.S 40 EM.C.S 206000 M 4 T >7
9 UMA-6345 23 B V G2 DM 35 LN 68000 F 2.5 PT >7
10 ASWINI-6189 26 B IV G3 IUGR 34 LN 72000 M 1.8 PT >7
11 BALA-6237 19 B V P PET 35 LN 106000 F 2.8 T >7  
12 GOMATHY-6543 29 UB V G4 PT 33 LN 46000 M 2.3 PT 5-7 mild RDS
13 NALINI-6431 27 B V G2 PPROM 34 EM.C.S 86000 F 2.9 PT >7
14 JOTHY-6447 24 B V G2 GDM 37 FORCEPS 172000 M 3.6 PT >7
15 ANBU-6789 22 B V P PT 30 LN 52000 M 1.8 VPT >7
16 PARIMALA-6679 20 B V P PT 35 LN 73500 M 2.7 PT >7
17 DHAVAMANI-6810 23 B V P PET 34 EM.C.S 42000 F 2.2 PT 5-7 mild RDS
18 MAHADEVI-7010 24 B III G2 PT 32 LN 55000 M 2.5 VPT >7
19 SAHIRA-7202 27 B V G3 PT 34 LN 140000 F 3.1 PT >7
20 LATHA-7148 24 B V P C.S 40 EL.C.S 182000 F 3.2 T >7
21 PADMAVATHY-7156 20 B V P C.S 39 EM.C.S 189000 M 3 T >7
22 PRAMILA-7246 27 B V G2 PT 33 LN 58000 M 2.2 PT >7
23 DEVIKA-7237 22 UB V P PET 35 LN 78000 F 2.6 PT >7
24 VANAJA-7317 23 B V P PET 34 LN 42000 M 2.1 PT 5-7 mild RDS
25 RAMYA-7287 22 B IV P PT 30 LN 59000 F 1.8 VPT >7
26 SATHYA-7295 21 B V P PT 35 FORCEPS 86000 M 2.5 PT >7
Sl. No NAME/IP NO. Age B/UB SES Gravidity
Risk
Factor GA
Mode of
delivery LBC SexB.Wt. GA Apgar
RDS
Scoring Mortality
27 ANJAL-ANNE-7456 26 B V G3 GDM 40 VACUUM 82500 M 3.2 T >7
28 CHANDRA-7689 18 B V P PT 34 LN 39000 M 2.1 PT <5 severe RDS  +
29 CATHERINE-7897 26 B IV G2 C.S 38 EL.C.S 192000 F 2.8 T >7
30 KOTHAI-7793 24 B V P PPROM 30 LN 32000 F 1.6 VPT <5 severe RDS  +
31 NITHYA-7987 23 B V P PT 31 LN 56000 M 1.8 VPT >7
32 MOHANA-8002 26 UB V G3 PET 35 EL.C.S 72000 F 2.3 PT >7
33 SOPHIA-8006 20 B V P PT 34 LN 69000 M 2.5 PT >7
34 SUDHA-7995 26 B V G3 C.S 38 EL.C.S 278000 F 2.8 T >7
35 REVATHY-8018 23 B V P GDM 38 LN 288000 F 3 T >7
36 SASI-8216 22 B V G2 PT 33 LN 33000 M 1.6 PT >7
37 AMBIKA-8218 21 B V P PPROM 35 EM.C.S 64000 F 2.3 PT >7
38 SELVI-8217 21 B V P PT 31 LN 23000 F 2.3 VPT >7
39 KUMUDHA-8246 24 B IV P PT 35 LN 135000 M 2.9 PT >7
40 LAKSHMI-8300 27 UB V G2 PT 33 LN 82000 M 2.8 PT >7
41 HAJIRA-BANU-8433 26 UB V G2 C.S 35 EL.C.S 96800 F 2.7 PT >7
42 VIJAYA-8480 32 B V G3 PT 32 LN 48000 F 2.3 PT >7
43 SANGEETHA-8565 26 B III P C.S 37 EM.C.S 182000 M 3.1 PT >7
44 KAVITHA-8569 19 B V P PT 35 EM.C.S 36000 F 2.1 PT 5-7 mild RDS  +
45 THAYAMMAL-8600 21 UB V P PET 34 LN 76000 M 2.6 PT >7
46 BAGYAM-8720 22 B V P PET 35 LN 52000 M 2.1 PT >7
47 MAHESWARI-9208 22 B IV G2 PT 31 LN 50000 M 2 VPT >7
48 KALIAMMAL-9246 26 B V G2 GDM 38 LN 179000 F 3 T >7
49 BAIRAVI-9925 23 B V P C.S 34 EL.C.S 65000 M 2 PT 5-7 mild RDS
50 RANI-10026 22 B V P PT 35 LN 52000 F 2.6 PT >7
51 SARADHA-10224 19 B V P PT 31 LN 54000 M 1.4 VPT >7
52 PANGAJAM-10986 21 B V P PPROM 35 LN 122000 F 2.1 PT >7
53 SUSHILA-10046 31 B V P GDM 35 EM.C.S 93800 F 3.6 PT >7
Sl. No NAME/IP NO. Age B/UB SES Gravidity
Risk
Factor GA
Mode of
delivery LBC SexB.Wt. GA Apgar
RDS
Scoring Mortality
54 DEIVANAI-11026 28 B IV G3 PPROM 34 EM.C.S 220000 M 2.25 PT >7
55 RAMANI-11463 24 UB V G2 PT 34 FORCEPS 66000 M 2.1 PT >
56 PONNAMMAL-11256 23 B V G2 PET 32 LN 38000 M 1.8 PT <5 severe RDS  +
57 SUMATHY-11098 26 B V G3 PPROM 35 LN 78000 M 2.25 PT >7
58 PREMA-008 29 B V G2 PET 35 LN 72000 F 2.1 PT >7
59 SHANTHA-026 23 B V G2 PT 32 EM.C.S 33000 M 1.9 PT >7
60 RADHIKA-073 21 B V P PT 34 LN 96000 M 2.6 PT >7
61 JOTHY-146 27 UB V G2 PT 34 LN 58000 M 2.6 PT >7
62 GEETHA-722 26 B V P PET 30 LN 40000 F 2.2 VPT >7
63 KARPAGM-906 22 B IV P PT 35 LN 178000 M 2.8 PT >7
64 SUJI-1028 18 B V P PET 31 LN 23000 M 1.6 VPT 5-7 mild RDS
65 VEDHA-1543 24 B V G2 C.S 37 EM.C.S 82000 F 2.2 PT 5-7 mild RDS
66 SAMSATH-2037 22 UB V P PT 31 LN 36000 M 1.6 VPT 5-7 mild RDS
67 RUBA-2249 21 B V P C.S 40 EL.C.S 98000 F 3.6 T >7
68 DEEPA-2878 26 B V G3 PT 34 LN 84000 M 2.4 PT >7
69 SOUNDARAM-3040 18 B IV P PPROM 35 LN 92000 F 2.8 PT >7
70 VASANTHI-3725 20 B V P PT 33 LN 38000 F 2.8 PT >7
71 ASHA-4023 22 B III P DM 36 EM.C.S 85000 M 3 PT >7
72 CHELLAM-4218 28 B V G2 GDM 39 LN 93600 M 3.4 T >7
73 KARUPPAYI-4137 21 B V G2 PT 35 LN 68000 F 2.2 PT >7
74 RADHA-4173 31 B V G2 PET 28 LN 8000 M 1 VPT <5 severe RDS  +
75 MARY-4256 21 B V P PPROM 36 LN 184000 M 2.8 PT >7
76 PARVEEN-4448 25 B IV P PT 37 FORCEPS 126000 F 2.75 PT >7
77 SUGANTHI-4256 26 B V G3 IUGR 34 LN 45000 M 1.6 PT <5 severe RDS  +
78 SARASU-4789 29 B V G4 C.S 40 EL.C.S 134000 F 3.25 T >7
79 KASTHURI-4926 26 B V G3 PT 35 LN 110000 M 2.8 PT >7
80 USHA-4898 24 B V G2 C.S 39 EL.C.S 152000 M 3.2 T >7
Sl. No NAME/IP NO. Age B/UB SES Gravidity
Risk
Factor GA
Mode of
delivery LBC SexB.Wt. GA Apgar
RDS
Scoring Mortality
81 BANU-5125 23 B V G2 PT 29 LN 32000 F 1.6 VPT 5-7 mild RDS
82 KAMATCHI-5278 26 B V G3 PT 32 LN 58000 M 2.1 PT >7
83 THILAGA-5254 24 B IV G2 C.S 38 EL.C.S 92000 M 3.2 T >7
84 SAVITHA-5310 26 B V G2 GDM 37 EM.C.S 120000 M 3.1 PT >7
85 VALLI-5355 20 B V P PT 35 EM.C.S 68000 M 2 PT >7
86 DHANAM5446 23 UB V G2 C.S 40 EL.C.S 86000 F 3 T >7
87 MUKKAYI-5567 22 B V G3 C.S 38 EM.C.S 82000 M 2.8 T >7
88 KANNAGI-5569 32 B V P PT 28 LN 6600 F 1.1 VPT <5 severe RDS  +
89 FATHIMA-5800 21 B V G4 PPROM 34 LN 52000 M 1.8 PT 5-7 mild RDS
90 PATCHI-5925 28 B V P PET 34 LN 88000 M 2.6 PT >7
91 FLORENCE-5968 26 B III G2 PT 30 LN 50000 F 1.8 VPT >7
92 MARIAMMAL-6120 28 B V G3 PT 31 LN 50000 M 2 VPT >7
93 PRABHA-6134 18 B IV P C.S 40 EL.C.S 135000 F 3 T >7
94 JEYANTHI 24 UB V P PPROM 35 EM.C.S 42000 F 2.4 PT 5-7 mild RDS
95 VADIVU-6258 24 B V P PT 30 LN 36000 M 1.8 VPT >7
96 SHEELA-6145 21 B IV G2 GDM 38 VACUUM 140000 F 3.2 T >7
97 SAROJA-6334 22 B V P PT 35 LN 58000 M 2.6 PT >7
98 SHANTHI-6447 28 B V P PET 34 LN 96000 M 2.25 PT >7
99 CHITHRA-6578 21 B V P PT 32 EM.C.S 86000 F 2.2 PT >7
100 GOMATHY-6876 22 B V P PT 33 LN 66000 M 2.1 PT >7
B - Booked DM - Diabetes Mellitus T - Term
UB - Unbooked GDM - Gestational Diabetes Mellitus PT - Preterm
SES - Socio Econmic Status C.S - Cesarean Section VPT - Very Preterm
P - Primi EL.C.S - Elective Cesarean Section LN - Labour Natural
GA - Gestational Age EM.C.S - Emergency Cesarean Section PET -- Preeclamptic toxemia 
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